Premium
Novel Targets and Therapeutics for Bone Loss
Author(s) -
MARGOLIS RONALD N.,
WIMALAWANSA SUNIL J.
Publication year - 2006
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1346.040
Subject(s) - anabolic agents , osteoporosis , anabolism , disease , medicine , bioinformatics , bone development , intensive care medicine , computational biology , neuroscience , biology , pathology , endocrinology
Advances in the treatment of osteoporosis over the past decade have resulted in the generation of novel therapeutic agents aimed at providing both anticatabolic and anabolic effects in bone. In‐depth understanding of the biology of key factors regulating bone metabolism has begun to reveal new approaches to treating this costly and debilitating disease. During the next decade we will observe the development and evolution of several new classes of therapeutic targets and agents to combat this disease.